Warning Letter Pilot Could Muddy Compliance Waters, Attorney Maintains
This article was originally published in The Gray Sheet
Executive SummaryFDA's proposed warning letter pilot program could have the unintended effect of making it harder for industry to interpret certain compliance-related "gray areas," Thomas Muldoon, a partner in the Chicago law firm of Burditt & Radzius, asserted Oct. 27 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.